The Long Haul
For some people infected with COVID-19, the disease does not end with the swift resolution of all symptoms.
Last year, Sudipto Mukherjee, MD, MPH, a hematologist at Cleveland Clinic working with patients who have recovered...
Online Exclusives
European Commission Approves Selinexor Plus Dexamethasone for Relapsed/Refractory Myeloma
Selinexor, in combination with dexamethasone, has been granted conditional marketing authorization by the European Commission (EC) for the treatment of adult patients with multiple...
FDA Approves Isatuximab-irfc Combination for Relapsed/Refractory Myeloma
Isatuximab-irfc, in combination with carfilzomib and dexamethasone (Isa-Kd), was approved by the U.S. Food and Drug Administration (FDA) on March 31, 2021 for the...
News
From the Blood Journals
HLA-Haploidentical Relative and Matched Unrelated Donor Transplant Lead to Similar Survival...
Transplantation with an HLA-haploidentical relative donor is associated with similar two-year survival rates compared with transplantation with a matched unrelated donor in patients with...
Ixazomib Combination Improves PFS Versus Placebo in Patients With Transplant-Ineligible Myeloma
When researchers added ixazomib to continuous lenalidomide-dexamethasone (Rd) in patients with newly diagnosed, transplant-ineligible multiple myeloma (MM), they observed that the treatment regimen was...
Multimedia
Deepu Madduri: Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
Deepu Madduri, MD, discusses data from the phase Ib/II CARTITUDE-1 study evaluating chimeric antigen receptor (CAR) T cell therapy ciltacabtagene autoleucel in patients with...
Steven Pipe: Etranacogene Dezaparvovec Gene Therapy for Hemophilia B
Steven Pipe, MD, shares safety and efficacy data from a phase III study of etranacogene dezaparvovec gene therapy in patients with hemophilia B.
Charlotte Bradbury: Adding Mycophenolate to Corticosteroid for ITP
Mycophenolate alongside corticosteroids may be considered as an effective first-line treatment option for some patients with immune thrombocytopenia. Charlotte Bradbury, MD, discusses results from...
José Blanco: Accessory Splenectomy in Patients with Immune Cytopenias
José Blanco, MD, discusses whether searching for an accessory spleen or performing accessory splenectomy is a safe and effective treatment for patients with refractory...
On Location
Researchers Recommend New Processes for Bone Marrow Screening for HLH
For patients suspected of having hemophagocytic lymphohistiocytosis (HLH), bone marrow biopsy is often used to...
e-IRON: Iron-Deficiency Anemia Management at Warp Speed
A telemedicine pilot program to triage and expedite the management of patients with iron-deficiency anemia...
TPO-RAs and ITP: Eltrombopag Induces High Efficacy, But Avatrombopag Offers Advantages
A pair of studies presented at the 2020 American Society of Hematology Annual Meeting analyzed...
No Difference in CNS Relapse Rate According to Prophylaxis Route
According to results from a retrospective analysis of central nervous system (CNS) prophylaxis in patients...
Researchers Validate Burkitt Lymphoma Prognostic Index
Researchers have created a prognostic index specific to Burkitt lymphoma (BL) that will allow for...
Thiotepa-Containing Conditioning Regimens Improve Survival Outcomes in Patients With PCNSL
Thiotepa-containing conditioning regimens, including thiotepa/busulfan/cyclophosphamide (TBC) and thiotepa/carmustine (TT-BCNU), were associated with favorable survival outcomes...
Latest Headlines
ASH Directions
ASH Announces First Round of Research Restart Awardees, 2020 ASH Annual Report Now Available,...
ASH Announces First Round of Research Restart Awardees
The American Society of Hematology (ASH) has announced the names of 19 early-career investigators who will receive critical...
New Clinical Practice Guidelines for VTE in Cancer, Registration for 2021 Highlights of ASH®...
Now Published: ASH Clinical Practice Guidelines on VTE in Patients with Cancer
ASH’s new clinical practice guideline on the prevention and treatment of venous thromboembolism...
Remembering Emil Freireich, Millie Hughes-Fulford, and more
Remembering Emil Freireich (1927 – 2021)
Renowned hematologist and researcher Emil Freireich, MD, died on February 1, 2021, at the age of 93.Dr. Freireich had...
Remembering Art Nienhuis, Thomas Edgington, and more
Remembering Art Nienhuis (1941 – 2021)
Gene therapy pioneer Art Nienhuis, MD, passed away on February 3, 2021, at the age of 79.Dr. Nienhuis was...
Remembering James Cook, Oncology Researchers Receive 2020 NIH Director’s New Innovator Awards, and more
Remembering James Cook (1936 – 2020)
James D. Cook, MD, an esteemed teacher and mentor, passed away in November 2020. His research focused on iron...
The Long Haul
For some people infected with COVID-19, the disease does not end with the swift resolution of all symptoms.
Last year, Sudipto Mukherjee, MD, MPH, a...
Examining the Blood-Brain Barrier
The prognosis for patients with non-Hodgkin lymphoma (NHL) who develop central nervous system (CNS) relapse is dismal, and there are few clear answers about...
Charting the Myeloma Immunotherapy Landscape
A bevy of forthcoming immunotherapies for multiple myeloma over the next few years raises hopes, as well as questions about combinations, sequencing, and potential...